CN110691589A - 用于治疗血液病的化合物和组合物 - Google Patents

用于治疗血液病的化合物和组合物 Download PDF

Info

Publication number
CN110691589A
CN110691589A CN201880022870.5A CN201880022870A CN110691589A CN 110691589 A CN110691589 A CN 110691589A CN 201880022870 A CN201880022870 A CN 201880022870A CN 110691589 A CN110691589 A CN 110691589A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
heterocyclyl
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880022870.5A
Other languages
English (en)
Chinese (zh)
Inventor
V.R.冈马迪
S.萨马达
K.内洛尔
G.达吉纳卡特
W.R.巴拉苏布拉马尼安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurigene Oncology Ltd
Original Assignee
Aurigene Discovery Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Ltd filed Critical Aurigene Discovery Technologies Ltd
Priority to CN202510475412.9A priority Critical patent/CN120267671A/zh
Publication of CN110691589A publication Critical patent/CN110691589A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201880022870.5A 2017-03-31 2018-03-30 用于治疗血液病的化合物和组合物 Pending CN110691589A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510475412.9A CN120267671A (zh) 2017-03-31 2018-03-30 用于治疗血液病的化合物和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201741011785 2017-03-31
IN201741011785 2017-03-31
PCT/IB2018/052232 WO2018178947A2 (en) 2017-03-31 2018-03-30 Compounds and compositions for treating hematological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510475412.9A Division CN120267671A (zh) 2017-03-31 2018-03-30 用于治疗血液病的化合物和组合物

Publications (1)

Publication Number Publication Date
CN110691589A true CN110691589A (zh) 2020-01-14

Family

ID=63677680

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510475412.9A Pending CN120267671A (zh) 2017-03-31 2018-03-30 用于治疗血液病的化合物和组合物
CN201880022870.5A Pending CN110691589A (zh) 2017-03-31 2018-03-30 用于治疗血液病的化合物和组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202510475412.9A Pending CN120267671A (zh) 2017-03-31 2018-03-30 用于治疗血液病的化合物和组合物

Country Status (25)

Country Link
US (2) US11419875B2 (enExample)
EP (2) EP3600270B1 (enExample)
JP (2) JP7333136B2 (enExample)
KR (3) KR20240019391A (enExample)
CN (2) CN120267671A (enExample)
AU (2) AU2018242623B2 (enExample)
BR (1) BR112019018991A2 (enExample)
CA (1) CA3056893A1 (enExample)
DK (1) DK3600270T3 (enExample)
EA (1) EA201992322A3 (enExample)
ES (1) ES2950764T3 (enExample)
FI (1) FI3600270T3 (enExample)
HR (1) HRP20230657T8 (enExample)
HU (1) HUE062648T2 (enExample)
IL (4) IL305150B2 (enExample)
LT (1) LT3600270T (enExample)
MX (2) MX389825B (enExample)
PH (1) PH12019502138A1 (enExample)
PL (1) PL3600270T3 (enExample)
PT (1) PT3600270T (enExample)
RS (1) RS64411B1 (enExample)
SG (1) SG11201908171TA (enExample)
SI (1) SI3600270T1 (enExample)
SM (1) SMT202300236T1 (enExample)
WO (1) WO2018178947A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022135338A1 (zh) * 2020-12-25 2022-06-30 南京明德新药研发有限公司 酰胺噁唑类化合物
CN114773331A (zh) * 2021-01-22 2022-07-22 武汉人福创新药物研发中心有限公司 苯并咪唑化合物及其用途
CN115785064A (zh) * 2021-11-19 2023-03-14 成都奥睿药业有限公司 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
WO2023116866A1 (zh) * 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ722019A (en) 2014-01-13 2022-07-01 Aurigene Discovery Tech Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
IL305150B2 (en) 2017-03-31 2025-03-01 Aurigene Oncology Ltd Compounds and preparations for the treatment of hematological disorders
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
EP3998264B1 (en) * 2019-07-10 2025-08-20 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Oxazole compound as multi-targeted inhibitor of irak4 and btk
CN112480101B (zh) * 2019-09-12 2022-11-25 中国科学院上海药物研究所 一类irak4激酶抑制剂及其制备和应用
PL4097099T3 (pl) 2020-02-07 2024-11-04 Gasherbrum Bio, Inc. Heterocykliczne agonisty glp-1
CA3179378A1 (en) 2020-04-07 2021-10-14 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
JP2023537477A (ja) * 2020-08-03 2023-09-01 キュリス，インコーポレイテッド 疾患及び障害を治療するための組成物及び方法
MX2023005591A (es) * 2020-11-18 2023-05-29 Curis Inc Metodos de tratamiento de enfermedades y trastornos.
EP4319750A4 (en) * 2021-04-08 2025-02-26 Curis, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101072775A (zh) * 2004-12-17 2007-11-14 伊莱利利公司 新的mch受体拮抗剂
CN102470127A (zh) * 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
CN102480966A (zh) * 2009-06-12 2012-05-30 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
WO2013042137A1 (en) * 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
WO2017009806A1 (en) * 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Substituted aza compounds as irak-4 inhibitors
WO2017023941A1 (en) * 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds
CN106456619A (zh) * 2014-01-13 2017-02-22 奥列基因发现技术有限公司 作为irak4抑制剂的二环杂环衍生物

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
ES2102367T3 (es) 1990-05-18 1997-08-01 Hoechst Ag Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
WO2004099156A1 (en) 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
WO2004103954A1 (ja) 2003-05-20 2004-12-02 Ajinomoto Co., Inc. アミド誘導体
US20050004133A1 (en) 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7338950B2 (en) 2003-10-07 2008-03-04 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
US20090005249A1 (en) 2004-04-22 2009-01-01 Bayer Cropscience Lp Method and composition for controlling weeds
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655297A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
AU2005304393B2 (en) 2004-11-10 2012-09-27 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
ATE446962T1 (de) 2004-12-17 2009-11-15 Lilly Co Eli Thiazolopyridinon-derivate als mch- rezeptorantagonisten
EP1674467A1 (en) 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
AU2007215247B2 (en) 2006-02-10 2012-12-13 Transtech Pharma, Llc Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
GB0606429D0 (en) 2006-03-30 2006-05-10 Novartis Ag Organic compounds
US8008481B2 (en) 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
WO2007121154A2 (en) 2006-04-11 2007-10-25 Janssen Pharmaceutica, N.V. Substituted benzothiazole kinase inhibitors
AU2007292924A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
KR20090049076A (ko) 2006-09-07 2009-05-15 바이오겐 아이덱 엠에이 인코포레이티드 인터루킨-1 수용체-결합 키나제 조절물질로서 인다졸 유도체
WO2008061109A2 (en) 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
US7998995B2 (en) 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
WO2008156614A2 (en) * 2007-06-14 2008-12-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
EP2170834B1 (en) 2007-07-16 2014-01-08 AbbVie Inc. Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
JP5508265B2 (ja) 2007-08-08 2014-05-28 メルク セローノ ソシエテ アノニム 多発性硬化症の治療のための、スフィンゴシン１−ホスフェート（ｓ１ｐ）受容体に結合する６−アミノ−ピリミジン−４−カルボキサミド誘導体及び関連化合物
US20090221612A1 (en) 2008-02-13 2009-09-03 Mitchell Scott A Certain substituted amides, method of making, and method of use thereof
EP2303886A2 (en) * 2008-06-24 2011-04-06 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
WO2010059602A2 (en) 2008-11-19 2010-05-27 Schering Corporation Inhibitors of diacylglycerol acyltransferase
US8283360B2 (en) 2008-12-19 2012-10-09 Merck Sharp & Dohme Corp. Bicyclic heterocyclic derivatives and methods of use thereof
SG172382A1 (en) 2008-12-23 2011-07-28 Hoffmann La Roche Dihydropyridone ureas as p2x7 modulators
PL2488486T3 (pl) 2009-10-13 2020-01-31 Ligand Pharmaceuticals Inc. Małocząsteczkowe związki mimetyczne hematopoetycznego czynnika wzrostu i ich zastosowania
CN102939283B (zh) 2010-04-22 2015-06-03 詹森药业有限公司 可用作己酮糖激酶抑制剂的吲唑化合物
CA2793697A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Inhibitors of phosphoinositide dependent kinase 1 (pdk1)
SI2585064T1 (sl) 2010-06-24 2017-08-31 Chemocentryx, Inc. Antagonisti C5AR
MX340490B (es) 2010-07-13 2016-07-11 F Hoffmann-La Roche Ag * Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
CN103298792A (zh) 2010-11-19 2013-09-11 利亘制药公司 杂环胺及其用途
JP6007189B2 (ja) 2010-12-20 2016-10-12 メルク セローノ ソシエテ アノニム Ｉｒａｋ阻害剤としてのインダゾリルトリアゾール誘導体
CN103608017B (zh) 2011-04-12 2017-02-15 美国卫生和人力服务部 用于治疗或预防疟疾的疟原虫表面阴离子通道抑制剂
TWI605043B (zh) * 2011-10-14 2017-11-11 安比特生物科學公司 雜環化合物及其使用方法
US9957271B2 (en) 2011-10-20 2018-05-01 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
KR101385603B1 (ko) 2012-05-17 2014-04-21 한국원자력의학원 벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en) 2012-06-29 2014-01-03 Hanmi Pharm. Co., Ltd. Fused pyrimidine derivatives having inhibitory activity on fms kinases
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
EP2914592B1 (en) 2012-11-03 2017-10-11 Boehringer Ingelheim International GmbH Inhibitors of cytomegalovirus
CA2907960C (en) 2013-05-22 2021-10-19 Children's Hospital Medical Center Combination therapy for mds
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
WO2015104662A1 (en) 2014-01-10 2015-07-16 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
BR112016017996A2 (pt) 2014-02-06 2017-08-08 Abbvie Inc 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
MX2016017147A (es) 2014-06-20 2017-06-07 Aurigene Discovery Tech Ltd Compuestos de indazole substituidos como inhibidores de irak4.
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
US20180201609A1 (en) 2015-07-15 2018-07-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
CA3038130A1 (en) 2016-10-28 2018-05-03 Children's Hospital Medical Center Treatment of diseases associated with activated irak
IL305150B2 (en) 2017-03-31 2025-03-01 Aurigene Oncology Ltd Compounds and preparations for the treatment of hematological disorders
SI3704108T1 (sl) 2017-10-31 2024-07-31 Curis, Inc. Inhibitor irak4 v kombinaciji z inhibitorjem bcl-2 za uporabo pri zdravljenju raka

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101072775A (zh) * 2004-12-17 2007-11-14 伊莱利利公司 新的mch受体拮抗剂
CN102480966A (zh) * 2009-06-12 2012-05-30 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
CN102470127A (zh) * 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
WO2013042137A1 (en) * 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
CN106456619A (zh) * 2014-01-13 2017-02-22 奥列基因发现技术有限公司 作为irak4抑制剂的二环杂环衍生物
WO2017009806A1 (en) * 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Substituted aza compounds as irak-4 inhibitors
WO2017023941A1 (en) * 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GARRETT WESLEY RHYASEN: "IRAK family kinases as therapeutic targets for Myelodysplastic Syndrome and Acute Myeloid Leukemia", 《DISSERTATION OF UNIVERSITY OF CINCINNATI》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022135338A1 (zh) * 2020-12-25 2022-06-30 南京明德新药研发有限公司 酰胺噁唑类化合物
CN116745294A (zh) * 2020-12-25 2023-09-12 南京明德新药研发有限公司 酰胺噁唑类化合物
CN114773331A (zh) * 2021-01-22 2022-07-22 武汉人福创新药物研发中心有限公司 苯并咪唑化合物及其用途
CN115785064A (zh) * 2021-11-19 2023-03-14 成都奥睿药业有限公司 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
WO2023088435A1 (zh) * 2021-11-19 2023-05-25 成都奥睿药业有限公司 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
CN115785064B (zh) * 2021-11-19 2024-12-06 成都奥睿药业有限公司 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
WO2023116866A1 (zh) * 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
US12195479B2 (en) 2021-12-23 2025-01-14 Hangzhou Polymed Biopharmaceuticals, Inc. Five- and six-membered compound, and preparation method therefor and pharmaceutical composition and use thereof

Also Published As

Publication number Publication date
WO2018178947A2 (en) 2018-10-04
PL3600270T3 (pl) 2023-09-25
JP2023154005A (ja) 2023-10-18
IL269536A (en) 2019-11-28
NZ757707A (en) 2023-09-29
US20210290628A1 (en) 2021-09-23
HUE062648T2 (hu) 2023-11-28
MX2022001343A (es) 2022-03-17
JP7333136B2 (ja) 2023-08-24
PH12019502138A1 (en) 2020-06-29
IL293783B2 (en) 2024-01-01
FI3600270T3 (fi) 2023-07-20
AU2018242623A1 (en) 2019-10-17
JP2020512343A (ja) 2020-04-23
KR102633530B1 (ko) 2024-02-02
EA201992322A2 (ru) 2020-07-31
EP3600270A4 (en) 2020-08-26
IL316364A (en) 2024-12-01
CN120267671A (zh) 2025-07-08
IL305150B1 (en) 2024-11-01
IL293783A (en) 2022-08-01
SG11201908171TA (en) 2019-10-30
IL269536B (en) 2022-07-01
MX389825B (es) 2025-03-20
AU2018242623B2 (en) 2024-05-02
HRP20230657T1 (hr) 2023-10-13
US20220339161A1 (en) 2022-10-27
LT3600270T (lt) 2023-08-25
KR20250065441A (ko) 2025-05-12
BR112019018991A2 (pt) 2020-04-14
HRP20230657T8 (hr) 2023-11-10
DK3600270T3 (da) 2023-07-10
KR20240019391A (ko) 2024-02-14
IL305150A (en) 2023-10-01
EP4252853A3 (en) 2023-12-13
AU2024203943A1 (en) 2024-07-04
SMT202300236T1 (it) 2023-09-06
EP3600270B1 (en) 2023-06-14
MX2019011158A (es) 2019-10-17
US11419875B2 (en) 2022-08-23
EP4252853A2 (en) 2023-10-04
KR20190130023A (ko) 2019-11-20
IL293783B1 (en) 2023-09-01
CA3056893A1 (en) 2018-10-04
SI3600270T1 (sl) 2023-10-30
ES2950764T3 (es) 2023-10-13
EA201992322A3 (ru) 2020-09-30
EP3600270A2 (en) 2020-02-05
IL305150B2 (en) 2025-03-01
PT3600270T (pt) 2023-07-25
RS64411B1 (sr) 2023-09-29

Similar Documents

Publication Publication Date Title
US20220339161A1 (en) Compounds and compositions for treating hematological disorders
AU2023222890B2 (en) Compounds and compositions for treating hematological disorders
HK40013355A (en) Compounds and compositions for treating hematological disorders
NZ757707B2 (en) Compounds and compositions for treating hematological disorders
HK40031549A (en) Compounds and compositions for treating hematological disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013355

Country of ref document: HK

CB02 Change of applicant information

Address after: bangalore

Applicant after: Aoruijin Tumor Co.,Ltd.

Address before: bangalore

Applicant before: AURIGENE DISCOVERY TECHNOLOGIES LTD.

CB02 Change of applicant information